The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

GLP-1 drugs indirectly reduce inflammation through weight loss. The meds can also activate certain T cells — white blood cells key to the immune system — which can have anti-inflammatory effects.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

In 2014, the FDA approved their use to treat obesity. The drugs activate the GLP-1 receptor on cells in the pancreas and other organs, stimulating insulin release, which in turn lowers blood sugar ...

The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements ...

The Verdiva pipeline also includes a once-weekly oral drug designed to target and activate amylin. The company said this drug could be used as a monotherapy or in combination with an oral GLP-1 ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...